Another explanation for the mutual exclusivity is that mutations in KRAS and BRAF may be functionally incompatible; BRAF mutations would thus have unfavorable effects in KRAS-mutant CRC and vice versa, consequently leading to elimination of cells that have acquired both mutations sequentially. The gene discussed is KRAS; the disease is colorectal carcinoma.